These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Immunotherapy: a new option for advanced prostate cancer. Harv Mens Health Watch; 2010 Sep; 15(2):1-2. PubMed ID: 20941869 [No Abstract] [Full Text] [Related]
4. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer. McKarney I Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575 [TBL] [Abstract][Full Text] [Related]
5. New treatments for metastic prostate cancer. Med Lett Drugs Ther; 2010 Sep; 52(1346):69-70. PubMed ID: 20814400 [TBL] [Abstract][Full Text] [Related]
6. Concerns about Provenge simmer as CMS ponders coverage. Goozner M J Natl Cancer Inst; 2011 Feb; 103(4):288-9. PubMed ID: 21303996 [No Abstract] [Full Text] [Related]
7. Cellular immunotherapy licensed for advanced prostate cancer. Traynor K Am J Health Syst Pharm; 2010 Jun; 67(11):862. PubMed ID: 20484204 [No Abstract] [Full Text] [Related]
9. Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches. Arlen PM Oncology (Williston Park); 2011 Mar; 25(3):261-2. PubMed ID: 21548469 [No Abstract] [Full Text] [Related]
10. What Nurses and Patients Need to Know About Sipulecucel-T Immunotherapy for Prostate Cancer. Becze E ONS Connect; 2015 Jun; 30(2):40-1. PubMed ID: 26146750 [No Abstract] [Full Text] [Related]
11. Prostate cancer immunology - an update for Urologists. Rajarubendra N; Lawrentschuk N; Bolton DM; Klotz L; Davis ID BJU Int; 2011 Apr; 107(7):1046-51. PubMed ID: 21070575 [TBL] [Abstract][Full Text] [Related]